ISSN: 1734-1922
Archives of Medical Science Special Issues
Current issue Archive Archives of Medical Science
3/2007
 
Share:
Share:
abstract:

Invited review
The role of trimetazidine in inhibiting cardiomyocyte apoptosis

Yin Ruixing

Arch Med Sci 2007; 3, 3A: S17-S24
Online publish date: 2008/01/10
View full text Get citation
 
Trimetazidine is a clinically effective cellular anti-ischaemic agent that has no negative inotropic or vasodilator properties. It is conventionally used mainly for patients with coronary or cerebrovascular disease. Recent studies demonstrated that trimetazidine also has an important role in protecting against ischaemia-reperfusion injury by inhibiting cardiomyocyte apoptosis in a rabbit model of ischaemia-reperfusion. The possible mechanisms of trimetazidine in inhibiting cardiomyocyte apoptosis might be due to the combined effects of limiting Na+ and Ca2+ accumulation and reducing intracellular acidosis during low-flow simulated ischaemia, improving myocardial energy metabolism and modulating mitochondrial permeability transition during myocardial ischaemia, increasing endogenous antioxidant capacity and protecting against oxygen free radical-induced toxicity, as well as inhibiting neutrophil infiltration and attenuating the myocardial inflammatory reaction. But this remains to be identified definitively.
keywords:

trimetazidine, apoptosis, myocardium, mechanism

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.